Innovative treatments for septicemia – Septiscreen
The incidence of sepsis is continually increasing, with 300 cases per 100,000 per year in the US. Mortality is still in the order of 30-50% resulting in 800,000 deaths per year in the US. In most cases the pathogens involved are sensitive to commonly used antibiotics but treatment is insufficient due to host factors including massive inflammation, microvasculature dysfunction and vascular leak, among others. A central assumption of this project is that there is a necessity for drugs targeting these host responses to complement antibiotic treatment. We reason that once an infection has reached a certain threshold, bacterial killing by antibiotics is restricted by biofilm-like resistance mechanisms and that furthermore, bacterial killing is not sufficient to prevent the adverse effects of infection on blood vessels. The strategy of this project is to perform a pharmacological screen to find molecular entities targeting the host pathways/receptors that block the pathogenic interaction of bacteria with the endothelium: bacterial colonization, junction destabilization and inflammation processes. We will use Neisseria meningitidis as the model of a sepsis causing pathogen as it recapitulates many key features of sepsis pathology and because of recent progress in understanding the mechanisms underlying the disease caused by this bacterium. Identified compounds will then be tested with two other sepsis causing pathogens, Pseudomonas aeruginosa and Staphylococcus aureus. We expect to generate a selection of compounds that can then be developed into drugs to treat deadly bacterial infections.
Monsieur Guillaume Dumenil (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - DELEGATION REGIONALE DE PARIS V) – firstname.lastname@example.org
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - DELEGATION REGIONALE DE PARIS V
Sanofi-Aventis SANOFI-AVENTIS RECHERCHE &DEVELOPPEMENT
Help of the ANR 399,651 euros
Beginning and duration of the scientific project: December 2011 - 36 Months